Compare THG & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THG | BIO |
|---|---|---|
| Founded | 1852 | 1952 |
| Country | United States | United States |
| Employees | N/A | 7450 |
| Industry | Property-Casualty Insurers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 7.1B |
| IPO Year | 1996 | N/A |
| Metric | THG | BIO |
|---|---|---|
| Price | $177.43 | $293.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | $194.60 | ★ $339.75 |
| AVG Volume (30 Days) | 271.1K | ★ 271.8K |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | ★ 55.21 | N/A |
| EPS | ★ 18.16 | N/A |
| Revenue | ★ $6,594,400,000.00 | N/A |
| Revenue This Year | $3.04 | $2.74 |
| Revenue Next Year | $4.24 | $3.20 |
| P/E Ratio | $9.76 | ★ $9.72 |
| Revenue Growth | ★ 5.72 | N/A |
| 52 Week Low | $155.93 | $211.43 |
| 52 Week High | $188.18 | $343.12 |
| Indicator | THG | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 53.66 | 62.83 |
| Support Level | $173.68 | $262.08 |
| Resistance Level | $177.72 | $311.09 |
| Average True Range (ATR) | 3.45 | 7.35 |
| MACD | 0.45 | 2.53 |
| Stochastic Oscillator | 59.35 | 85.42 |
The Hanover Insurance Group Inc is a holding company whose primary business is offering property and casualty insurance products and services. The company markets itself through independent agents and brokers in the United States while conducting business through Hanover Insurance, Citizens and other THG subsidiaries. The company conducts business operations through four operating segments: Core Commercial, Specialty, Personal Lines, and Other. The company operates an investment portfolio that is exposed to fixed-income securities.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.